Submitted by als2076 on August 12, 2020 - 10:18am
| Title | Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma. |
| Publication Type | Journal Article |
| Year of Publication | 2019 |
| Authors | Musselman K, Glynn S, Mosquera JMiguel, Elemento O, Sboner A, Beltran H, Holcomb K |
| Journal | Gynecol Oncol Rep |
| Volume | 28 |
| Pagination | 54-57 |
| Date Published | 2019 May |
| ISSN | 2352-5789 |
| Abstract | Uterine serous adenocarcinoma is a rare but highly malignant form of endometrial cancer, comprising over 50% of recurrences and deaths from endometrial cancer. We report a case of a 68-year old woman with recurrent uterine serous adenocarcinoma who underwent molecular testing and genetic sequencing of her tumor. She was found to have focal amplification of ERBB2 confirmed by amplification and overexpression of HER2/ fluorescence hybridization and immunohistochemistry. Given the identification of this potential target and progression of disease, trastuzumab was added to the patient's chemotherapy regimen with ultimate complete response. |
| DOI | 10.1016/j.gore.2019.01.013 |
| Alternate Journal | Gynecol Oncol Rep |
| PubMed ID | 30906838 |
| PubMed Central ID | PMC6411491 |